Docs won’t prescribe pricey new cholesterol meds unless they lower heart risks
Docs won’t prescribe pricey new cholesterol meds unless they lower heart risks

When the first injectable medicines for lowering cholesterol were launched last year, Wall Street was looking for blockbuster sales. Instead, the products have, so far, been a disappointment. The price tags are high and some patients still resist injections….MOREhttps://www.statnews.com/pharmalot/2016/04/07/cholesterol-statin-heart-atack/

Our Institutes
our location
ARPI::American Research and Policy Institute Suite 700 1250 Connecticut Ave, NW Washington, DC 20036
Contact Us